dry eyes and joint pains. The presence of anti-SSA antibodies and diminished results of the Schirmer test supported the diagnosis of Sjögren's syndrome; thus, hydroxychloroquine and prescription of artificial tears were started. Symptomatic treatment was begun because the development of albumin and total protein inversion suggested plasma cell dyscrasia. Further work-up for immunofixation electrophoresis and bone marrow biopsy confirmed IgG lambda-positive MM. She was subsequently treated with VRD (bortezomib, lenalidomide, and dexamethasone), followed by an autologous BMT in May 2024. Post-transplant maintenance was given with lenalidomide. She also developed sensory neuropathy, which was managed with pregabalin, with no recurrence of MM on follow-up. **Discussion:** The case epitomizes the complex diagnostic interplay between MM and Sjögren's syndrome. Symptoms of fatigue and protein abnormalities can easily be attributed to an autoimmune condition, with a delayed diagnosis of MM. Multidisciplinary collaboration has been critical for management of comorbidities and assurance of timely diagnosis. The patient responded well to BMT and maintenance therapy, proving personalized care. Furthermore, long-term treatment shows the necessity of monitoring drug-induced neuropathy. This case report adds to the growing awareness of rare concomitant autoimmune disorders and hematologic malignancies, with a reminder for vigilance in complex presentations and the delivery of adaptive multidisciplinary care.

Keywords: Multiple Myeloma, Sjögren's Syndrome, Bone Marrow Transplantation, Lenalidomide, Neuropath.

https://doi.org/10.1016/j.htct.2024.11.076

PP 49

PRIMARY PALATAL ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA: RARITY TREATED SUCCESSFULLY WITH BRENTUXIMAB VEDOTIN

Müjgan Çözeli [1,*], Elif Canbolat Hirfanoğlu [1], Birol Güvenç [2]

[1] *Cukurova University Medical Faculty Hospital, Department of Internal Medicine*
[2] *Cukurova University Medical Faculty Hospital, Department of Internal Medicine, Division of Hematology*

Introduction: ALCL is an extremely rare T-cell non-Hodgkin lymphoma subtype made up of CD30-positive tumor cells, which are very aggressive. Though it most frequently involves lymph nodes and skin, less frequently, it affects other organs as well. Primary oral involvement, particularly of the palate, is highly uncommon. The paper reports a peculiar case of localized primary ALK-negative ALCL of the palate in a 73-year-old female patient treated successfully with brentuximab vedotin, pointing to the importance of identifying atypical presentations. **Case Report:** A 73-year-old female with a history of presenting a painless ulcer on her palate, which did not heal with local treatments for two months, presented to the otolaryngology clinic and underwent an incisional biopsy. Histopathological findings showed large atypical lymphoid cells with prominent nucleoli, consistent with ALCL. Immunohistochemical staining was positive for CD30 and negative for ALK; in addition, Epstein-Barr virus testing returned negative. PET-CT showed localized uptake of FDG in the palate, SUVmax 8.5, with no significant lymphadenopathy and no systemic involvement. Bone marrow biopsy showed normal hematopoiesis with no evidence of infiltration. The patient was diagnosed with primary breast ALK-negative ALCL and started on brentuximab vedotin. The patient went into complete remission after three cycles of therapy with no residual disease evident on follow-up imaging. **Discussion:** This case illustrates the need to consider ALCL in the differential diagnosis of atypical sites, such as the palate, when lesions fail to respond to conventional therapy. Early biopsy and a wide panel of immunohistochemical tests are crucial for accurate diagnosis. Due to the high recurrence rates as well as poor prognosis associated with ALK-negative ALCL, highly active targeted therapies include brentuximab vedotin. The complete remission attained in this patient underlines the promise of personalized therapies in dealing with rare malignancies. Awareness of such atypical presentations may help in early diagnoses and improve patient outcomes. This case further stresses that management of lymphoma with such unusual presentations may be effectively accomplished using an interdisciplinary approach.

Keywords: anaplastic large cell lymphoma, ALK-negative, CD30, brentuximab vedotin, palatal lymphoma.

https://doi.org/10.1016/j.htct.2024.11.077

PP 50

PRIMARY EXTRAMEDULLARY PLASMACYTOMA OF THE LYMPH NODES

Ali Turunç [1,*], Birol Güvenç [1]

[1] *Cukurova University Medical Faculty Hospital, Department of Internal Medicine, Division of Hematology*

Introduction: Extramedullary plasmacytomas are rare malignant neoplasms that can arise in various organs; however, lymph node involvement is uncommon. The cervical lymph nodes are most frequently affected. We present the case of a 68-year-old female diagnosed with a primary extramedullary plasmacytoma involving multiple lymph nodes, primarily in the cervical region. **Case Report:** A 68-year-old female patient presented with a one-month history of progressive enlargement and painful swelling of the right subclavicular and cervical areas. Imaging revealed pathological lymphadenopathy, and excisional biopsy was performed from the right cervical level 5 lymph node. Histopathological analysis confirmed the diagnosis of a plasmacytoma. A subsequent bone marrow biopsy revealed normocellular marrow without any evidence of infiltration. Positron emission tomography-CT staging